During the American Association for Cancer Research Annual Meeting 2022, researchers discussed ways to improve chimeric antigen receptor T-cell therapy's efficacy in solid tumors. These included sussing out differences between solid and blood cancers in their susceptibility to CAR T cells’ cytotoxicity, taking a modular approach to engineering next-generation agents, and building in breaks for exhaustion-prone CAR T cells to restore their function.

You do not currently have access to this content.